Skip to main content
. 2019 Mar 19;3(6):875–883. doi: 10.1182/bloodadvances.2018027599

Table 4.

Toxicities experienced by donors on this study and CIBMTR control group

Plerixafor RDSafe P
Number of donors 64 1098
Number of centers 12 42
Maximum toxicity at collection, n (%) <.001
 0 19 (30) 188 (17)
 1 34 (53) 411 (38)
 2 10 (16) 328 (30)
 3-4 1 (2) 164 (15)
Maximum toxicity at 1 mo, n (%) .538
 0 33 (60) 520 (54)
 1 14 (25) 308 (32)
 2 8 (15) 111 (11)
 3-4 0 29 (3)
Recovery at 1 mo, n (%)
 Yes 43 (67) 590 (62) .440
 No 21 (33) 356 (38)
 Unknown 0 152